-
J&J Reports Q4 and Full-Year 2023 Results with Strong MedTech and Pharmaceutical Growth
•
Johnson & Johnson (J&J; NYSE: JNJ), a US major, has released its financial results for the fourth quarter and full year of 2023. Fourth-quarter global sales increased by 7.2% excluding currency impacts to USD 21.4 billion, while full-year revenues rose by 7.4% year-on-year (YOY) to USD 85.16 billion. Both the…
-
Establishment Labs Launches Motiva Breast Implants in China
•
Establishment Labs Holdings Inc., (NASDAQ: ESTA), a US-based medical technology company specializing in women’s health, has announced the official market launch of its Motiva brand breast implants in China. The company’s product line includes the Motiva Flora tissue expander, which is designed to enhance the outcomes of breast reconstruction post-breast…
-
Jiuzhou Pharmaceutical Expands with $42 Million Investment in Japanese CRO Services
•
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a Chinese pharmaceutical company, has declared plans to invest USD 42 million in the establishment of a wholly-owned subsidiary in Japan that will offer Contract Research Organization (CRO) services. This strategic expansion will be executed through Jiuzhou’s existing wholly-owned subsidiary, Raybow Life Sciences（Singapore）Pte…
-
Zylox-Tonbridge Medical Technology Secures NMPA Nod for Innovative Iliac Vein Stent System
•
Zylox-Tonbridge Medical Technology (HKG: 2190), a leading developer of nerve and peripheral vascular interventional devices based in China, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its ZYLOX Penguin iliac vein stent system. This innovative product is designed for the treatment of…
-
Eisai’s Uric Acid Excretion Drug Urece Accepted for Review in China
•
The Center for Drug Evaluation (CDE) in China has indicated on its website that it has accepted for review the New Drug Application (NDA) filed by Japan-based Eisai (TYO: 4523) for its drug Urece (dotinurad). This marks a significant step towards potentially bringing the uric acid excretion promoting drug to…
-
Hansoh Pharmaceutical Gets NMPA Approval for Type 2 Diabetes and Obesity Drug Trial
•
Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading Chinese pharmaceutical company, has announced that it has received approval from the National Medical Products Administration (NMPA) in China to commence a clinical study of its Category 1 drug candidate, HS-10501. The study aims to assess the efficacy and safety of…
-
Jiangsu Wuzhong Pharmaceutical’s Aesthetics Subsidiary Wins Approval for Facial Filler in China
•
Jiangsu Wuzhong Pharmaceutical Group Corp., (SHA: 600200), a prominent player in the Chinese pharmaceutical industry, has announced that its medical aesthetics subsidiary’s polylactic acid facial filler, AestheFill, has received marketing approval in China. The product is slated to become available in mainland China in the first half of 2024. AestheFill,…
-
Lepu Medical Technology Gains NMPA Approval for Innovative Coronary Device
•
Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading Chinese provider of cardiovascular disease solutions, has received marketing approval from the National Medical Products Administration (NMPA) for its self-developed coronary mastoid balloon dilation catheter. The device, classified as a Category III medical device, is indicated for balloon dilation in…
